About Matrix metalloproteinase-23
Matrix metalloproteinase-23 (MMP23B) is a protein
from Homo sapiens identified by UniProt accession
O75900, 390 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Matrix metalloproteinase-23 |
|---|
| UniProt accession | O75900 |
|---|
| Gene | MMP23B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 390 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (69)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.21
- ulcerative colitis · score 0.19
- body height · score 0.09
- neoplasm · score 0.09
- melanoma · score 0.08
- esophageal squamous cell carcinoma · score 0.07
- oral squamous cell carcinoma · score 0.06
- systemic scleroderma · score 0.04
- fat body mass · score 0.04
- hip circumference · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75900-F1 | alphafold | PREDICTED | 76.04 | — |
Amino-acid sequence (390 residues)
MGRGARVPSE APGAGVERRW LGAALVALCL LPALVLLARL GAPAVPAWSA AQGDVAALGL SAVPPTRVPG PLAPRRRRYT LTPARLRWDH FNLTYRILSF PRNLLSPRET RRALAAAFRM WSDVSPFSFR EVAPEQPSDL RIGFYPINHT DCLVSALHHC FDGPTGELAH AFFPPHGGIH FDDSEYWVLG PTRYSWKKGV WLTDLVHVAA HEIGHALGLM HSQHGRALMH LNATLRGWKA LSQDELWGLH RLYGCLDRLF VCASWARRGF CDARRRLMKR LCPSSCDFCY EFPFPTVATT PPPPRTKTRL VPEGRNVTFR CGQKILHKKG KVYWYKDQEP LEFSYPGYLA LGEAHLSIIA NAVNEGTYTC VVRRQQRVLT TYSWRVRVRG
Explore Matrix metalloproteinase-23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets